These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25090943)

  • 21. Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats.
    Renken C; Fischer DC; Kundt G; Gretz N; Haffner D
    Nephrol Dial Transplant; 2011 Jan; 26(1):92-100. PubMed ID: 20615907
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular Mechanisms of "Antiphospholipid Antibodies" and Their Paradoxical Role in the Pathogenesis of "Seronegative APS".
    Misasi R; Longo A; Recalchi S; Caissutti D; Riitano G; Manganelli V; Garofalo T; Sorice M; Capozzi A
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33182499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiphospholipid syndrome: an update.
    Merashli M; Noureldine MH; Uthman I; Khamashta M
    Eur J Clin Invest; 2015 Jun; 45(6):653-62. PubMed ID: 25851448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiphospholipid antibodies in patients with retinal vascular occlusions.
    Giordano N; Senesi M; Battisti E; Traversi C; Mattii G; Palumbo F; Gennari C
    Acta Ophthalmol Scand; 1998 Feb; 76(1):128-9. PubMed ID: 9541454
    [No Abstract]   [Full Text] [Related]  

  • 25. Late conversion to mammalian target of rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: clinical experience in the last 5 years.
    Sola E; Lopez V; Gutierrez C; Cabello M; Burgos D; Molina MG; Hernandez D
    Transplant Proc; 2010 Oct; 42(8):2859-60. PubMed ID: 20970551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin.
    Pierangeli SS; Espinola RG; Liu X; Harris EN
    Circ Res; 2001 Feb; 88(2):245-50. PubMed ID: 11157679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of nitric oxide and antiphospholipid antibody-mediated thrombosis.
    Mineo C
    Curr Rheumatol Rep; 2013 May; 15(5):324. PubMed ID: 23519891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiphospholipid syndrome: a clinical perspective.
    Zuo Y; Shi H; Li C; Knight JS
    Chin Med J (Engl); 2020 Apr; 133(8):929-940. PubMed ID: 32265421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does rapamycin induce melanin formation? An
    Kumaran MS; Srivastava N; Vinay K; Bhardwaj S; Parsad D
    Indian J Dermatol Venereol Leprol; 2019; 85(3):330-332. PubMed ID: 30829293
    [No Abstract]   [Full Text] [Related]  

  • 30. The Long Journey of mTOR Inhibitors and the Long Path That Is Still Ahead.
    Tedesco Silva H
    Transplantation; 2018 Feb; 102(2S Suppl 1):S1-S2. PubMed ID: 29369969
    [No Abstract]   [Full Text] [Related]  

  • 31. Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma.
    Grgic T; Mis L; Hammond JM
    Ann Pharmacother; 2011 Jan; 45(1):78-83. PubMed ID: 21177421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiphospholipid syndrome, antiphospholipid antibodies, and atherosclerosis.
    Sherer Y; Shoenfeld Y
    Curr Atheroscler Rep; 2001 Jul; 3(4):328-33. PubMed ID: 11389799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo.
    Romay-Penabad Z; Montiel-Manzano MG; Shilagard T; Papalardo E; Vargas G; Deora AB; Wang M; Jacovina AT; Garcia-Latorre E; Reyes-Maldonado E; Hajjar KA; Pierangeli SS
    Blood; 2009 Oct; 114(14):3074-83. PubMed ID: 19628708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The paradox of sirolimus-induced immunosuppression and tumor control.
    Stucki L; Piguet V
    Dermatology; 2006; 213(1):3-5. PubMed ID: 16778418
    [No Abstract]   [Full Text] [Related]  

  • 35. Increased lipid peroxidation correlates with platelet activation but not with markers of endothelial cell and blood coagulation activation in patients with antiphospholipid antibodies.
    Martinuzzo ME; Forastiero RR; Kordich L; Carreras LO
    Br J Haematol; 2001 Sep; 114(4):845-51. PubMed ID: 11564073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pivotal role of endothelial protein C receptor for antiphospholipid antibody-mediated pathologies.
    Chu CQ
    Rheumatology (Oxford); 2022 Mar; 61(3):883-885. PubMed ID: 34324656
    [No Abstract]   [Full Text] [Related]  

  • 37. Autophagy: a new therapeutic target in cartilage injury and osteoarthritis.
    Lotz M; Caramés B
    J Am Acad Orthop Surg; 2012 Apr; 20(4):261-2. PubMed ID: 22474097
    [No Abstract]   [Full Text] [Related]  

  • 38. Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies.
    Pierangeli SS; Vega-Ostertag M; Harris EN
    Thromb Res; 2004; 114(5-6):467-76. PubMed ID: 15507280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful use of sirolimus in a patient with cardiac microangiopathy in primary antiphospholipid syndrome.
    Sartorelli S; De Luca G; Campochiaro C; Peretto G; Sala S; Esposito A; Busnardo E; Basso C; Thiene G; Dagna L
    Scand J Rheumatol; 2019 Nov; 48(6):515-516. PubMed ID: 30794015
    [No Abstract]   [Full Text] [Related]  

  • 40. Cutaneous manifestations in antiphospholipid syndrome.
    Caporuscio S; Sorgi ML; Nisticò S; Pranteda G; Bottoni U; Carboni I; Del Duca E; Pranteda G
    Int J Immunopathol Pharmacol; 2015 Jun; 28(2):270-3. PubMed ID: 25875603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.